Article

Baush & Lomb wins license rights to thrombolytic agent

Rochester, NY—Bayer HealthCare LLC's Biological Products Division has granted Bausch & Lomb (B&L) an exclusive worldwide license to its Plasmin technology for use in developing novel therapies for ocular conditions.

Rochester, NY-Bayer HealthCare LLC's Biological Products Division has granted Bausch & Lomb (B&L) an exclusive worldwide license to its Plasmin technology for use in developing novel therapies for ocular conditions.

The drug, which is derived from processed human plasma, could be used in treating multiple indications that currently require vitrectomy surgery, said Gary M. Phillips, MD, Bausch & Lomb's corporate vice president, global pharmaceuticals and vitreoretinal.

Bayer also is exploring Plasmin's use as a thrombolytic agent to dissolve blood clots in veins and arteries.

Further details were not disclosed.

The deal comes on the heels of news that the FDA has accepted Bausch & Lomb's new drug application for its Retisert intravitreal implant for non-infectious uveitis. The implant, which is designed to deliver fluocinolone acetonide to the back of the eye for up to 3 years, is on the FDA's Fast Track list and has received orphan drug status.

Since the drug is part of the FDA's Continuous Marketing Application Pilot 1 Program, the company hopes to receive FDA notification of the application status this spring, with commercialization targeted for later in 2005.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.